Tobira Therapeutics Inc

Most Recent

  • uploads///NASH pipeline
    Company & Industry Overviews

    Understanding Gilead Sciences’ NASH Pipeline

    Simtuzumab is Gilead Sciences’ (GILD) most advanced NASH (nonalcoholic steatohepatitis) anti-fibrotic product.

    By Jillian Dabney
  • uploads///NASH opportunity
    Company & Industry Overviews

    Allergan Enters the Attractive NASH Market

    Although hepatitis C is the most common cause resulting in liver transplants today, NASH (nonalcoholic steatohepatitis) will replace it by 2030.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.